This program is supported by an independent education grant from Johnson & Johnson. This education program is only available to healthcare professionals in the USA.

In this live virtual roundtable, leading relapsed/refractory multiple myeloma (RRMM) experts Dr Ajay Nooka, MD, MPH, FACP and Dr Joshua Richter, MD will explore the rapidly evolving therapeutic landscape of B-cell maturation antigen (BCMA)-directed bispecific antibodies (BsAbs) and combination strategies. This dynamic, 60-minute faculty-led conversation will address real-world challenges in translating BCMA-directed BsAb and CD38 combination data into clinical practice, including outpatient or hybrid delivery models, infection risk mitigation during continuous therapy, and treatment sequencing decisions in RRMM. The discussion will focus on translating the latest clinical trial data into routine practice, overcoming operational barriers to treatment delivery, and resolving clinical hesitation surrounding novel combination regimens.

Through an interactive Q&A session, participants will have the opportunity to engage directly with the faculty to reinforce their understanding and address pressing clinical challenges. Ultimately, healthcare providers will gain actionable, evidence-based strategies to optimize treatment sequencing, implement standardized safety protocols, and confidently navigate complex patient relapses in the community oncology setting.

Credits: 1.0 AMA PRA Category 1 Credits™

Session Highlights

• Implementing Outpatient and Hybrid Delivery of BCMA BsAbs: Faculty will use real-world practice scenarios to guide the safe implementation of outpatient or hybrid step-up dosing (SUD), focusing closely on optimal patient selection, rigorous monitoring protocols, and seamless multidisciplinary coordination.
• Preventing Infection-Related Morbidity During Continuous BCMA Therapy: This segment focuses on mitigating infection risk during prolonged BCMA-directed therapy through standardized prophylaxis, regular immunoglobulin monitoring, and strategic dosing adaptations. It also features a brief patient advocate insight highlighting the real-world impact of recurrent infections and treatment interruptions on patient care.
• Optimizing Treatment Sequencing and Combination Therapy in RRMM: Participants will examine the latest clinical trial data comparing the efficacy and safety of BCMA BsAb combination therapy against both monotherapy and alternative second-line regimens, while actively addressing the clinical misconceptions that often limit appropriate treatment sequencing.

Who Should Watch

This program is designed for healthcare professionals who are involved in the diagnosis, treatment, and ongoing management of patients with relapsed/refractory multiple myeloma (RRMM) and seek to confidently translate emerging bispecific antibody evidence and combination strategies into real-world clinical practice.

• Community Hematologists/Oncologists
• Academic Hematologists/Oncologists
• Oncology Nurses and Nurse Practitioners (NPs)
• Physician Assistants (PAs)
• Oncology Pharmacists

Faculty

Dr Ajay K. Nooka, MD, MPH, FACP, is a Professor of Hematology and Medical Oncology at Emory University School of Medicine, where he serves as Director of the Myeloma Program and Associate Director of Clinical Research at the Winship Cancer Institute. Specializing in multiple myeloma and plasma cell disorders, his research focuses on improving risk stratification and evaluating novel therapies, including CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates. A globally recognized expert, Dr. Nooka serves on the steering committee of the Multiple Myeloma Research Consortium (MMRC) and holds editorial positions at leading journals, including Cancer and Clinical Lymphoma, Myeloma and Leukemia.

Dr Joshua Richter, MD is an Associate Professor of Medicine in the Division of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai and serves as the Director of Multiple Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai. Specializing in multiple myeloma and related plasma cell disorders, his clinical and translational research focuses on the design and implementation of clinical trials evaluating novel therapeutics, including bispecific antibodies, CAR T-cell therapies, and innovative combination regimens. A dedicated educator and prominent voice in the hematology community, Dr. Richter frequently presents his research at major international oncology conferences and is deeply committed to optimizing treatment sequencing and side-effect management to improve patient outcomes.

Continuing Education Information

Commercial support: This activity received monetary support through an independent education grant from Johnson & Johnson.

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Disclosures

Dr Ajay Nooka has disclosed financial relationships within the past 24 months with the following ineligible companies: Consultant / Advisor: AstraZeneca, Blue Earth Diagnostics, GlaxoSmithKline, Janssen, KITE, ONK Therapeutics, OPNA, Pfizer, Sebia, Perspective Informatics and Premier Research. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr Nooka does not intend to discuss non-FDA uses of drug products and/or devices only in relation to products for which he has no financial relationships.

Dr Joshua Richter has disclosed financial relationships within the past 24 months with the following ineligible companies: Consultant / Advisor: Janssen, BMS, Pfizer, Karyopharm, Sanofi, Takeda, Genentech, Abbvie, Regeneron, Forus, Menarini, Kite/Arcellx, UB Therapeutics. Speakers bureau: Janssen, BMS, Sanofi, Adaptive Biotechnologies, Pfizer. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr Richter does not intend to discuss non-FDA uses of drug products and/or devices only in relation to products for which she has no financial relationships.

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. All relevant financial relationships for anyone associated with the content of this activity were mitigated prior to the release of this program.

Activity Accreditation for Health Professions

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

• When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
• Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.

Participation Costs

There is no cost to participate in this program.

This continuing education activity is active starting August 6th 2026, and will expire on August 6th 2026.

Estimated time to complete this activity: 60 minutes.